Public Health Emergency - Leading a Nation Prepared
Date: September 15, 2011
Company: Neumedicines, Inc., Pasadena, Calif.
Contract amount: Approximately $17 million over 18 months and can be extended for a total of five years and up to $274 million
About the contract: Neumedicines will conduct studies to begin evaluating the safety and efficacy of a drug to treat bone marrow injuries from exposure to high levels of radiation, such as after a nuclear attack, and will develop manufacturing processes for the drug and manufacture small amounts of the drug for testing. The contract builds on work conducted under a BARDA contract issued in 2008. Under that contract, Neumedicines conducted studies indicating that the drug known as NMIL12-1 or HemaMax mitigates bone marrow damage caused by acute ionizing (damaging) radiation 24 hours after a person is exposed to radiation and that the drug promotes regeneration of multiple types of blood cells.
Additional information: BARDA is seeking additional proposals for products that potentially could treat or illness and injury from acute radiation syndrome, as well as improved diagnostic tools to measure the radiation dose a person has absorbed after a nuclear denotation or radiation accident.
Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at www.fbo.gov.
Procurement Announcement: Contract Award under BAA-BARDA-09-34
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages